HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The potential of proteasome inhibitors in cancer therapy.

AbstractBACKGROUND:
The ubiquitin-proteasome system has become a promising novel molecular target in cancer due to its critical role in cellular protein degradation, its interaction with cell cycle and apoptosis regulation and its unique mechanism of action.
OBJECTIVE:
This review focuses both on preclinical results and on data from clinical trials with proteasome inhibitors in cancer.
METHODS:
Results in hematological malignancies and solid tumors were included, and important data presented in abstract form were considered in this review.
RESULTS/CONCLUSION:
Bortezomib as first-in-class proteasome inhibitor has proven to be highly effective in some hematological malignancies, overcomes conventional chemoresistance, directly induces cell cycle arrest and apoptosis, and also targets the tumor microenvironment. It has been granted approval by the FDA for relapsed multiple myeloma, and recently for relapsed mantle cell lymphoma. Combination chemotherapy regimens have been developed providing high remission rates and remission quality in frontline treatment or in the relapsed setting in multiple myeloma. The combination of proteasome inhibition with novel targeted therapies is an emerging field in oncology. Moreover, novel proteasome inhibitors, such as NPI-0052 and carfilzomib, have been developed. This review summarizes our knowledge of the ubiquitin-proteasome system and recent data from cancer clinical trials.
AuthorsJan Sterz, Ivana von Metzler, Jens-Claus Hahne, Britta Lamottke, Jessica Rademacher, Ulrike Heider, Evangelos Terpos, Orhan Sezer
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 17 Issue 6 Pg. 879-95 (Jun 2008) ISSN: 1744-7658 [Electronic] England
PMID18491989 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Neoplasm Proteins
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Pyrazines
  • Ubiquitin
  • Bortezomib
Topics
  • Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Boronic Acids (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Bortezomib
  • Cell Line, Tumor (drug effects)
  • Clinical Trials as Topic (statistics & numerical data)
  • Combined Modality Therapy
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Hematologic Neoplasms (drug therapy, metabolism, surgery)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Neoplasm Proteins (antagonists & inhibitors, metabolism)
  • Neoplasms (drug therapy, enzymology)
  • Protease Inhibitors (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Proteasome Inhibitors
  • Protein Processing, Post-Translational (drug effects, physiology)
  • Pyrazines (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Salvage Therapy
  • Ubiquitin (physiology)
  • Ubiquitination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: